Levofloxacin, Amoxicillin, and Omeprazole as First-line Triple Therapy for Helicobacter pylori Eradication

Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial

“…Fluoroquinolones such as LEV have been used successfully in combination with PPI and AMO in the treatment of H pylori infection both as first-line25 26 and second-line26 27 therapy. In this study, LEV250-ST or LEV500-ST were significantly more effective than CLA-ST with eradication rates of 96% and 96.8%, respectively, compared with 80.8% using CLA-ST, in the ITT analysis.…”

Randomized Trial on 14-Days Versus 7-Days of Esomeprazole, Moxifloxacin and Amoxicillin for Second-Line or Rescue Treatment of Helicobacter pylori Infection

“…This obvious increase in quinolone resistance certainly deserves further observation, especially in light of the currently ongoing discussion whether or not quinolone-containing PPI triple therapy could be an option for first-line treatment of H. pylori infection [18]. Recent studies in populations with a high rate of clarithromycin resistance suggest that a quinolone-containing PPI triple therapy may be a valuable option for first-line treatment of H. pylori infection [27,28]. Others demonstrated that standard PPI triple therapy followed by quinolone-containing PPI triple therapy is a superior strategy compared with the opposite order [29], which further confirms the importance of quinolone-containing triple therapy in second-line therapy as it is also recommended by recent consensus guidelines [2,3].…”

Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection

“…This obvious increase in quinolone resistance certainly deserves further observation, especially in light of the currently ongoing discussion whether or not quinolone‐containing PPI triple therapy could be an option for first‐line treatment of H. pylori infection [18]. Recent studies in populations with a high rate of clarithromycin resistance suggest that a quinolone‐containing PPI triple therapy may be a valuable option for first‐line treatment of H. pylori infection [27,28]. Others demonstrated that standard PPI triple therapy followed by quinolone‐containing PPI triple therapy is a superior strategy compared with the opposite order [29], which further confirms the importance of quinolone‐containing triple therapy in second‐line therapy as it is also recommended by recent consensus guidelines [2,3].…”